Compare Marsh & McLennan Companies, Inc. (MRSH) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Marsh & McLennan Companies, Inc. vs TG Therapeutics Inc — how do they compare? Marsh & McLennan Companies, Inc. trades at $175.76 (market cap $84.31B), while TG Therapeutics Inc trades at $55.37 (market cap $8.16B). The key difference: Marsh & McLennan Companies, Inc. is far larger — about 10.3× TG Therapeutics Inc's market cap, and Marsh & McLennan Companies, Inc. pays a 2.24% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Marsh & McLennan Companies, Inc. for 109 Days and TG Therapeutics Inc for 16 Days on average.
| MRSH | TGTX | |
|---|---|---|
Market Cap | $84.31B | $8.16B |
Volume | 3,948,947 | 1,735,121 |
Sector | Financials | Health |
52-Week High | $207.02 | $59.06 |
52-Week Low | $157.32 | $26.94 |
Typical Hold Time | 109 Days | 16 Days |
Enterprise Value | $104.99B | $8.37B |
Dividend Yield | 2.24% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Marsh (MRSH) trades at $175.76, up 1.21% on the day, with a bullish technical signal and strong earnings beats in recent quarters. The stock is supported by robust fundamentals, including a 25.72% ROE and 14.24% net income margin, alongside the recent acquisition of Accel Holdings announced on October 2, 2026. Revenue has grown steadily, reaching $27.0B in 2025, though profit margins have slightly softened.
The outlook remains positive with a consensus price target of $202.71, implying 15% upside, but risks include high valuation multiples and competitive pressures. Analysts are predominantly neutral, with 65% hold ratings, suggesting cautious optimism amid solid operational performance.
TG Therapeutics (TGTX) trades at $55.37, up 4.57% today, but faces a bearish technical signal with recent earnings misses. Strong revenue growth is driven by BRIUMVI, with 2026 guidance raised to $950 million, though profitability is pressured by investments. A shareholder investigation and volatile cash flows add uncertainty, while analyst consensus remains bullish with an $80.50 price target.
The outlook hinges on BRIUMVI's market share gains and subcutaneous formulation progress, offering upside if execution succeeds. Risks include the fiduciary investigation, competitive pressures, and reliance on a single product. The stock presents a high-risk, high-reward opportunity, with current valuation reflecting growth expectations but vulnerable to setbacks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Marsh & McLennan Companies, Inc.
Marsh & McLennan Companies Inc is a professional services firm that provides advice and solutions in the areas of risk, strategy, and human capital. The company operates through two main segments: risk and insurance services and consulting. In risk and insurance services, the firm offers services via Marsh (an insurance broker) and Guy Carpenter (a risk and reinsurance specialist). The consulting division comprises Mercer (a provider of human resource services) and Oliver Wyman (management and economic consultancy).
Read more on MRSH →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
